KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Cash from Financing Activities (2018 - 2025)

Esperion Therapeutics' Cash from Financing Activities history spans 8 years, with the latest figure at $30.2 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 13.81% year-over-year to $30.2 million; the TTM value through Dec 2025 reached $36.2 million, down 58.16%, while the annual FY2025 figure was $36.2 million, 58.16% down from the prior year.
  • Cash from Financing Activities reached $30.2 million in Q4 2025 per ESPR's latest filing, up from $10.7 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $213.4 million in Q4 2021 to a low of -$30.4 million in Q4 2022.
  • Average Cash from Financing Activities over 5 years is $23.7 million, with a median of $4.1 million recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 3546.52% in 2023, then crashed 3811.12% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $213.4 million in 2021, then tumbled by 114.23% to -$30.4 million in 2022, then skyrocketed by 114.73% to $4.5 million in 2023, then soared by 682.73% to $35.0 million in 2024, then dropped by 13.81% to $30.2 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Cash from Financing Activities are $30.2 million (Q4 2025), $10.7 million (Q3 2025), and $2.8 million (Q2 2025).